Inventaire - your friends and communities are your best library

Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure

Author

Jonathan Corren

Published in: Annals of Allergy, Asthma & Immunology

Date of publication: November 1, 2004

Language: English

Bibliographic databases:

Cites articles 30

Date

Title

Authors

June 1, 1984

Peptide leukotriene release after antigen challenge in patients sensitive to ragweed,Peptide Leukotriene Release after Antigen Challenge in Patients Sensitive to Ragweed
April 1, 1988

Release of leukotrienes in patients with bronchial asthma
September 1, 1988

Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children
September 1, 1991

Allergic rhinitis
July 1, 1991

Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes

, ,
September 1, 1993

The aerodynamic characteristics of cat allergen
February 1, 1995

The effects of intranasal steroids on nasal and pulmonary responses to cat exposure
February 1, 1996

Relationship of daytime asthma symptom frequency to morning peak expiratory flow
April 1, 1996

Cat antigen in homes with and without cats may induce allergic symptoms
November 1, 1998

The rising trends in asthma and allergic disease
June 1, 1998

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group
September 1, 1999

Allergic rhinobronchitis: the asthma-allergic rhinitis link
January 1, 1999

The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma
October 1, 2000

Quality of life in allergic rhinitis and asthma. A population-based study of young adults
November 1, 2000

Epidemiologic evidence for asthma and rhinitis comorbidity
May 1, 2000

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial
April 1, 2000

A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge
March 1, 2001

The role and remediation of animal allergens in allergic diseases
September 1, 2001

Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure
November 1, 2001

Allergic rhinitis and its impact on asthma
February 1, 2001

Correlation of airway obstruction and patient-reported endpoints in clinical studies
November 27, 2002

A randomized controlled trial of intravenous montelukast in acute asthma
June 1, 2002

Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall
July 1, 2002

Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring
May 1, 2002

The efficacy of montelukast in the treatment of cat allergen-induced asthma in children

, ,
November 1, 2002

Variability and lack of predictive ability of asthma end-points in clinical trials
January 1, 2003

Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation
February 1, 2003

Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis
December 1, 2003

Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period,Montelukast improves symptoms of seasonal allergic rhinitis over a 4‐week treatment period
June 1, 2003

Rhinitis and asthma: evidence for respiratory system integration

Article -

Welcome to inventaire

The library of your friends and communities

Learn more